Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours

European Journal of Immunology

Volumn 41, Issue 1, 2011, Pages 18-25

  Huang, Fang Ping ^a,b   Chen, Yu Xiao ^b,c   To, Christina K W ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Costimulations; DC; IL 10; Immunosuppression; Tumour vaccine

Indexed keywords

INTERLEUKIN 10; TUMOR ANTIGEN; TUMOR VACCINE;

ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL FUNCTION; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 78650374370     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040543     Document Type: Article

References (84)

1. Whiteside, T. L., Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006. 16: 3-15.
2. Greenberg, P. D., Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 1991. 49: 281-355.
3. Ossendorp, F., Mengede, E., Camps, M., Filius, R. and Melief, C. J., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 1998. 187: 693-702.
4. Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P. and Van Pel, A., Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994. 12: 337-365.
5. Burnet, F. M., The Clonal Selection Theory of Acquired Immunity. Cambridge University Press: Cambridge 1959.
6. Miller, J. F., Immunological function of the thymus. Lancet 1961. 2: 748-749.
7. Huang, F. P. and MacPherson, G. G., Continuing education of the immune system - dendritic cells, immune regulation and tolerance. Curr. Mol. Med. 2001. 1: 457-468.
8. Pardoll, D., Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 2003. 21: 807-839.
9. Cerottini, J. C., von Fliedner, V. and Boon, T., Recognition of tumor-associated antigens by T lymphocytes: from basic concepts to new approaches. Ann. Oncol. 1992. 3: 11-16.
10. Igney, F. H. and Krammer, P. H., Tumor counterattack: fact or fiction? Cancer Immunol. Immunother. 2005. 54: 1127-1136.
11. Schuler, G. and Steinman, R. M., Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 1997. 186: 1183-1187.
12. Reid, D. C., Dendritic cells and immunotherapy for malignant disease. Br. J. Haematol. 2001. 112: 874-887.
13. Mellman, I. and Steinman, R. M., Dendritic cells. specialized and regulated antigen processing machines. Cell 2001. 106: 255-258.
14. Banchereau, J. and Steinman, R. M., Dendritic cells and the control of immunity. Nature 1998. 392: 245-252.
15. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S. and Steinman, R. M., Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992. 176: 1693-1702.
16. Sallusto, F. and Lanzavecchia, A., Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994. 179: 1109-1118.
17. Caux, C., Dezutter-Dambuyant, C., Schmitt, D. and Banchereau, J., GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992. 360: 258-261.
18. Gilboa, E., Nair, S. K. and Lyerly, H. K., Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 1998. 46: 82-87.
19. Sornasse, T., Flammand, V., De Becker, G., Bazin, H., Tielemans, F., Thielemans, K., Urbain, J. et al., Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J. Exp. Med. 1992. 175: 15-22.
20. Flamand, V., Lespagnard, L., Thielemans, K., Leo, O., Urbain, J. and Moser, M., Enhancement of a spontaneous immune response against a B-cell lymphoma by dendritic cells leads to protection against the tumor. Ann. N. Y. Acad. Sci. 1993. 690: 382-384.
21. Young, J. W. and Inaba, K., Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 1996. 183: 7-11.
22. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J. et al., Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995. 1: 1297-1302.
23. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G. and Levy, R., Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996. 2: 52-58.
24. Bodey, B., Bodey Jr B., Siegel, S. E. and Kaiser, H. E., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 2000. 20: 2665-2676.
25. Andrews, D. M., Maraskovsky, E. and Smyth, M. J., Cancer vaccines for established cancer: how to make them better? Immunol. Rev. 2008. 222: 242-255.
26. Schuler, G., Dendritic cells in cancer immunotherapy. Eur. J. Immunol. 2010. 40: 2123-2130.
27. Liu, K., Victora, G. D., Schwickert, T. A., Guermonprez, P., Meredith, M. M., Yao, K., Chu, F. F. et al., In vivo analysis of dendritic cell development and homeostasis. Science 2009. 324: 392-397.
28. Liu, Y. J., Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001. 106: 259-262.
29. Steinman, R. M., Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 2007. 37: S53-S60.
30. Steinman, R. M., Turley, S., Mellman, I. ansd Inaba, K., The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 2000. 191: 411-416.
31. Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B. et al., Batf3 deficiency reveals a critical role for CD8alpha+dendritic cells in cytotoxic T cell immunity. Science 2008. 322: 1097-1100.
32. Bachem, A., Guttler, S., Hartung, E., Ebstein, F., Schaefer, M., Tannert, A., Salama, A. et al., Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+cells as homologues of mouse CD8+dendritic cells. J. Exp. Med. 2010. 207: 1273-1281.
33. Crozat, K., Guiton, R., Contreras, V., Feuillet, V., Dutertre, C. A., Ventre, E., Vu Manh, T. P. et al., The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+dendritic cells. J. Exp. Med. 2010. 207: 1283-1292.
34. Jongbloed, S. L., Kassianos, A. J., McDonald, K. J., Clark, G. J., Ju, X., Angel, C. E., Chen, C. J. et al., Human CD141+(BDCA-3)+dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 2010. 207: 1247-1260.
35. Poulin, L. F., Salio, M., Griessinger, E., Anjos-Afonso, F., Craciun, L., Chen, J. L., Keller, A. M. et al., Characterization of human DNGR-1+BDCA3+leukocytes as putative equivalents of mouse CD8alpha+dendritic cells. J. Exp. Med. 2010. 207: 1261-1271.
36. Finkelman, F. D., Lees, A., Birnbaum, R., Gause, W. C. and Morris, S. C., Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 1996. 157: 1406-1414.
37. Steinman, R. M., Hawiger, D. and Nussenzweig, M. C., Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003. 21: 685-711.
38. Liu, Q., Zhang, C., Sun, A., Zheng, Y., Wang, L. and Cao, X., Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J. Immunol. 2009. 182: 6207-6216.
39. Kalinski, P., Dendritic cells in immunotherapy of established cancer: roles of signals 1, 2, 3 and 4. Curr. Opin. Investig. Drugs 2009. 10: 526-535.
40. Specht, J. M., Wang, G., Do, M. T., Lam, J. S., Royal, R. E., Reeves, M. E., Rosenberg, S. A. and Hwu, P., Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 1997. 186: 1213-1221.
41. Song, E. S., Lee, V., Surh, C. D., Lynn, A., Brumm, D., Jolly, D. J., Warner, J. F. and Chada, S., Antigen presentation in retroviral vector-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 1997. 94: 1943-1948.
42. Gabrilovich, D., Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 2004. 4: 941-952.
43. Song, W., Kong, H. L., Carpenter, H., Torii, H., Granstein, R., Rafii, S., Moore, M. A. and Crystal, R. G., Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 1997. 186: 1247-1256.
44. Dallal, R. M. and Lotze, M. T., The dendritic cell and human cancer vaccines. Curr. Opin. Immunol. 2000. 12: 583-588.
45. Boczkowski, D., Nair, S. K., Snyder, D. and Gilboa, E., Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 1996. 184: 465-472.
46. Tuting, T., DeLeo, A. B., Lotze, M. T. and Storkus, W. J., Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol. 1997. 27: 2702-2707.
47. Gong, J., Chen, D., Kashiwaba, M. and Kufe, D., Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 1997. 3: 558-561.
48. Steinman, R. M. and Dhodapkar, M., Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 2001. 94: 459-473.
49. Koski, G. K., Cohen, P. A., Roses, R. E., Xu, S. and Czerniecki, B. J., Reengineering dendritic cell-based anti-cancer vaccines. Immunol. Rev. 2008. 222: 256-276.
50. Yang, Y., Huang, C. T., Huang, X. and Pardoll, D. M., Persistent toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 2004. 5: 508-515.
51. Rutella, S., Danese, S. and Leone, G., Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006. 108: 1435-1440.
52. Ojima, T., Iwahashi, M., Nakamura, M., Matsuda, K., Nakamori, M., Ueda, K., Naka, T. et al., Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int. J. Cancer 2007. 120: 585-593.
53. Liu, Y., Zhang, X., Zhang, W., Chen, Z., Chan, T., Ali, K., Jia, Z. and Xiang, J., Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther. 2002. 9: 202-208.
54. Hanks, B. A., Jiang, J., Singh, R. A., Song, W., Barry, M., Huls, M. H., Slawin, K. M. and Spencer, D. M., Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat. Med. 2005. 11: 130-137.
55. Townsend, S. E. and Allison, J. P., Tumor rejection after direct costimulation of CD8+T cells by B7-transfected melanoma cells. Science 1993. 259: 368-370.
56. Ma, L., Chan, K. W., Trendell-Smith, N. J., Wu, A., Tian, L., Lam, A. C., Chan, A. K. et al., Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains. Eur. J. Immunol. 2005. 35: 3364-3375.
57. Georgiev, M., Agle, L. M., Chu, J. L., Elkon, K. B. and Ashany, D., Mature dendritic cells readily break tolerance in normal mice but do not lead to disease expression. Arthritis Rheum. 2005. 52: 225-238.
58. Moore, K. W., Malefyt, R. D., Coffman, R. L. and O'Garra, A., Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001. 19: 683-765.
59. O'Garra, A., Barrat, F. J., Castro, A. G., Vicari, A. and Hawrylowicz, C., Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 2008. 223: 114-131.
60. Enk, A. H., Angeloni, V. L., Udey, M. C. and Katz, S. I., Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol. 1993. 151: 2390-2398.
61. Buelens, C., Verhasselt, V., De Groote, D., Thielemans, K., Goldman, M. and Willems, F., Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur. J. Immunol. 1997. 27: 756-762.
62. Ahern, P. P., Izcue, A., Maloy, K. J. and Powrie, F., The interleukin-23 axis in intestinal inflammation. Immunol. Rev. 2008. 226: 147-159.
63. Mantovani, A. and Pierotti, M. A., Cancer and inflammation: a complex relationship. Cancer Lett. 2008. 267: 180-181.
64. Dworak, H., Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986. 315: 1650-1659.
65. Chen, Q., Daniel, V., Maher, D. W. and Hersey, P., Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 1994. 56: 755-760.
66. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D. and Carbone, D. P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996. 2: 1096-1103.
67. Gottfried, E., Kreutz, M. and Mackensen, A., Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev. 2008. 19: 65-77.
68. Chen, Y. X. Man, K., Ling, G. S., Chen, Y., Sun, B. S., Cheng, Q., Wong, O. H. et al., A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J. Immunol. 2007. 179: 6009-6015.
69. Huang, F.-P., Chen, Y. X. and Kwan, M., Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10. US Regular Patent (Filed on: Dec. 14, 2007, Ref. No.: 11/957, 146; Publication Date: January 8, 2009, Publication No. 20090010948). US Patent & Trademark Office, USA. PCT Patent (Filed on: Dec. 17, 2007; Publication Date: June 19, 2008, Ref No: WO2008/071093).
70. Ding, Y., Chen, D., Tarcsafalvi, A., Su, R., Qin, L. and Bromberg, J. S., Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J. Immunol. 2003. 170: 1383-1391.
71. Hanada, T., Yoshida, H., Kato, S., Tanaka, K., Masutani, K., Tsukada, J., Nomura, Y. et al., Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003. 19: 437-450.
72. Kinjyo, I., Hanada, T., Inagaki-Ohara, K., Mori, H., Aki, D., Ohishi, M., Yoshida, H. et al., SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 2002. 17: 583-591.
73. Hong, B., Ren, W., Song, X. T., Evel-Kabler, K., Chen, S. Y. and Huang, X. F., Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells. Cancer Res. 2009. 69: 8076-8084.
74. Shen, L., Evel-Kabler, K., Strube, R. and Chen, S. Y., Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 2004. 22: 1546-1553.
75. Evel-Kabler, K., Song, X. T., Aldrich, M., Huang, X. F. and Chen, S. Y., SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 2006. 116: 90-100.
76. Shi, L., Luo, K., Xia, D., Chen, T., Chen, G., Jiang, Y., Li, N. and Cao, X., DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses. Blood 2006. 108: 2678-2686.
77. Liu, G., Ng, H., Akasaki, Y., Yuan, X., Ehtesham, M., Yin, D., Black, K. L. and Yu, J. S., Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur. J. Immunol. 2004. 34: 1680-1687.
78. Fairchild, P. J., Nolan, K. F. and Waldmann, H., Genetic modification of dendritic cells through the directed differentiation of embryonic stem cells. Methods Mol. Biol. 2007. 380: 59-72.
79. Wobser, M., Voigt, H., Houben, R., Eggert, A. O., Freiwald, M., Kaemmerer, U., Kaempgen, E. et al., Dendritic cell based antitumor vaccination: impact of functional indoleamine 2, 3-dioxygenase expression. Cancer Immunol. Immunother. 2007. 56: 1017-1024.
80. Kao, J. Y., Gong, Y., Chen, C. M., Zheng, Q. D. and Chen, J. J., Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol. 2003. 170: 3806-3811.
81. Ilarregui, J. M., Croci, D. O., Bianco, G. A., Toscano, M. A., Salatino, M., Vermeulen, M. E., Geffner, J. R. and Rabinovich, G. A., Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 2009. 10: 981-991.
82. Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R. et al., The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007. 450: 566-569.
83. Seyerl, M., Kirchberger, S., Majdic, O., Seipelt, J., Jindra, C., Schrauf, C. and Stockl, J., Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur. J. Immunol. 2009.
84. Tiberghien, P., Use of suicide genes in gene therapy. J. Leukoc. Biol. 1994. 56: 203-209.